Biodesix Closes Series D Financing
News Aug 30, 2012
The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC). Funding will also support clinical validation studies, product development, and ongoing collaborations with a number of biotechnology and pharmaceutical companies.
New Blood and Urine Tests Indicate Autism in ChildrenNews
New tests, developed by researchers at the University of Warwick, could lead to earlier diagnosis of the condition.READ MORE
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE